Eli Lilly's Foundayo (orforglipron), an oral GLP-1 receptor agonist, demonstrated superior efficacy in three Phase 3 ACHIEVE trials for type 2 diabetes, outperforming oral semaglutide and other comparators in reducing A1C and body weight. In the head-to-head ACHIEVE-3 trial, Foundayo showed 57.1% greater A1C reduction and 73.6% greater weight loss than oral semaglutide at the highest doses. Foundayo also achieved significant improvements in blood sugar control and weight loss in ACHIEVE-2 and ACHIEVE-5 trials compared to dapagliflozin and placebo, respectively. Lilly plans to submit Foundayo for FDA approval for type 2 diabetes treatment by the end of Q2 2026, potentially offering a convenient oral option without food or water restrictions for patients.
The alcohol use disorder (AUD) market is projected to expand at a 12.1% compound annual growth rate (CAGR) from 2026 to 2036, driven by unmet clinical needs and the development of novel therapies targeting new mechanisms like the 5-HT3 pathway and NO...
Novo Nordisk and Eli Lilly are competing in the obesity drug market with their GLP-1 pills, Wegovy and Foundayo, respectively. Both companies are preparing for Medicare to cover these drugs for weight loss at $50 per month starting July 1, which coul...
Eli Lilly's stock surged in premarket trading following positive results from a Phase 3 trial of its next-generation weight-loss drug, retatrutide. Presented at the American Diabetes Association conference, the trial showed that patients lost an aver...
A curated list of 50 high-quality dividend growth stocks has been tracked since September 1, 2024, focusing on valuation and future return potential. Year-to-date, this group underperformed broad indexes but included standout performers like LRCX and...
Eli Lilly's Foundayo (orforglipron) showed significant weight loss results in women across all menopause stages in the ATTAIN-1 and ATTAIN-2 trials, including those with type 2 diabetes. Women lost up to 30.4 lbs (14.4%) in perimenopause and up to 28...
